Literature DB >> 7762499

Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists' (CTT) Collaboration.

.   

Abstract

The Cholesterol Treatment Trialists' Collaboration aims to provide reliable information about the effects on mortality and morbidity of treatments that modify blood lipid levels for a wide range of patient populations and risk groups. This protocol prospectively defines study eligibility, the main questions to be addressed, and statistical methods to be used. Additionally, by establishing a register of ongoing and planned trials prior to any trial results being known, this systematic overview attempts to avoid the methodologic problems and potential data-dependency of a retrospective project. The collaboration expects to have individual patient data on > 60,000 subjects by the year 2000, including 12,000 women and 20,000 elderly subjects, and should have good power to examine any effects on non-coronary artery disease events. Overall, there should be about 1,900 non-coronary artery disease deaths and > 2,000 total cancer events.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7762499     DOI: 10.1016/s0002-9149(99)80744-9

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  17 in total

Review 1.  Prevention of ischaemic stroke.

Authors:  G Gubitz; P Sandercock
Journal:  BMJ       Date:  2000-12-09

Review 2.  A general assessment of the safety of HMG CoA reductase inhibitors (statins).

Authors:  Donald M Black
Journal:  Curr Atheroscler Rep       Date:  2002-01       Impact factor: 5.113

3.  Cardiovascular disease: Should statin therapy be expanded in patients with CKD?

Authors:  Kristen L Jablonski; Michel Chonchol
Journal:  Nat Rev Nephrol       Date:  2012-07-03       Impact factor: 28.314

4.  Analysis of combined data from heterogeneous study designs: an applied example from the patient navigation research program.

Authors:  Richard G Roetzheim; Karen M Freund; Don K Corle; David M Murray; Frederick R Snyder; Andrea C Kronman; Pascal Jean-Pierre; Peter C Raich; Alan Ec Holden; Julie S Darnell; Victoria Warren-Mears; Steven Patierno
Journal:  Clin Trials       Date:  2012-01-24       Impact factor: 2.486

5.  Bezafibrate in men with lower extremity arterial disease: randomised controlled trial.

Authors:  Tom Meade; Riaz Zuhrie; Claire Cook; Jackie Cooper
Journal:  BMJ       Date:  2002-11-16

6.  The World Health Organization--International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration: prospective collaborative overviews of major randomized trials of blood pressure-lowering treatments.

Authors:  B Neal; S MacMahon
Journal:  Curr Hypertens Rep       Date:  1999-08       Impact factor: 5.369

7.  Does pravastatin promote cancer in elderly patients? A meta-analysis.

Authors:  Stefanos Bonovas; Nikolaos M Sitaras
Journal:  CMAJ       Date:  2007-02-27       Impact factor: 8.262

8.  Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

Authors:  Karen L Margolis; Barry R Davis; Charles Baimbridge; Jerry O Ciocon; Aloysius B Cuyjet; Richard A Dart; Paula T Einhorn; Charles E Ford; David Gordon; Thomas J Hartney; L Julian Haywood; Jordan Holtzman; David E Mathis; Suzanne Oparil; Jeffrey L Probstfield; Lara M Simpson; John D Stokes; Thomas B Wiegmann; Jeff D Williamson
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-06-10       Impact factor: 3.738

9.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.

Authors:  C Baigent; L Blackwell; J Emberson; L E Holland; C Reith; N Bhala; R Peto; E H Barnes; A Keech; J Simes; R Collins
Journal:  Lancet       Date:  2010-11-08       Impact factor: 79.321

10.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.

Authors:  B Mihaylova; J Emberson; L Blackwell; A Keech; J Simes; E H Barnes; M Voysey; A Gray; R Collins; C Baigent
Journal:  Lancet       Date:  2012-05-17       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.